NCT03170141View on ClinicalTrials.gov

Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2017

Primary Completion Date

July 31, 2027

Study Completion Date

December 31, 2027

Conditions
Glioblastoma Multiforme of BrainBrain Cancer
Interventions
BIOLOGICAL

Antigen-specific IgT cells

Tumor antigen-specific IgT cells are infused intravenously . Drug: cyclophosphamide 250 mg/m\^2 d1-3; Drug: Fludarabine 25mg/m\^2 d1-3

Trial Locations (1)

518000

Shenzhen Geno-immune Medical Institute, Shenzhen

All Listed Sponsors
lead

Shenzhen Geno-Immune Medical Institute

OTHER